Clinuvel Pharmaceuticals Ltd (CLVLF) stock

CLVLFOTCAmerican Depositary ReceiptsFiscal year ends June 30Also trades as CUVL

Financials through fiscal 2026, year ended Jun 30, 2026Last filing: 20-F on Oct 30, 2026Score 9/30

$5.05−0.33 (-6.13%)

Close on Oct 19, 2026Market cap $254.66MP/E 11.0Yield –

Clinuvel Pharmaceuticals pe ratio

The price-to-earnings ratio is the share price divided by diluted earnings per share over the trailing twelve months.

Clinuvel Pharmaceuticals's pe ratio was 11.0× on Nov 3, 2026, against 15.8× a year earlier. Over the last 2 years it ranged from 11.0× to 20.7×, with a median of 15.8×.

PE Ratio at the end of each year

Period	Period end	Value	Change (pts)
2026	Nov 3, 2026	11.0×	−7.4
2025	Dec 31, 2025	18.4×	+1.7
2024	Dec 31, 2024	16.7×	–

Where these numbers come from

Parsed from the XBRL in Clinuvel Pharmaceuticals's annual and quarterly filings with the SEC
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing